Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPDL3280A treatment after investigational imaging in advanced solid tumors
NL-OMON47630Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in Nonhematologic neoplasms, sponsored by University Medical Center Groningen. Primary endpoint: Objective response rate by RECIST v1.1. Started Feb 2016; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON47630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47630.